

The main shareholders issue a loan commitment

In order to maintain financial flexibility after the repayment of the bond, and until a long-term financing solution is in place, the main shareholders of Bactiguard have issued a loan commitment of up to SEK 50 million

Bactiguard has previously announced that it has secured the refinancing of the bond loan maturing December 12, 2016 through the company's cash position, a bank credit facility of SEK 100 million and an overdraft facility of SEK 30 million. The maturity of the utilized credit under the loan commitment is just over one year, until December 31, 2017.

The company is simultaneously working on ensuring a long-term financing solution. This process is ongoing but, until the long-term financing is in place, and also to be able to maintain financial flexibility after the repayment of the bond loan, the main shareholders of Bactiguard, Christian Kinch and Thomas von Koch have issued a loan commitment of up to SEK 50 million. Thereby Bactiguard will not need to utilize the overdraft facility for repayment of the bond loan.

The size of the utilized credit under this loan commitment from the main shareholders will be determined in connection with the repayment of the bond in December 2016. The loan from the main shareholders matures on June 30, 2018 and will be without collateral and otherwise on commercial terms corresponding with those that will apply to the bank loan of SEK 100 million.

For further information, please contact:

Fredrik Järsten, CFO, mobile: +46 72 550 00 89

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on November 9, 2016.

About Bactiguard

Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the Europe, Middle East, Asia, South America and Southern Africa. The company has market presence in some 50 countries and has about 60 employees. Its headquarters is located in Stockholm and production facilities in Sweden and Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com.